- NewsCategory：
- All Company news Industry news
common83One result
-
1010
4D Pharma collabor4D Pharma collaborates with MSπD to develop live biotherapeutic products for ₽α vaccinesates with MSD to develop l®↓Ωive biotherapeutic pro& ducts for vaccines
4D pharma plc, a leading ph✔₹ armaceutical company £♦ in the development of live biotherapeutics, ✔♥σ™today announces that the company haδ♠€s entered into a research coll"©>aboration agreement and an option license toα ε≈ use with MSD (trading name of Merck &©₩; Co., Inc., in Kenilworth , New Jersey , United ↓π♠States of America) to Discove'↔r and Develop Live Biotherapeutic Produc↔>ts ("LBP") for vaccines.Under the terms of the a≠×δ☆greement, MicroRx®, the proprietary platform of 4D, will be γ↔associated with MSD's expertise in the dev$↕elopment and commercialization of new vaccines§®✔, in order to discover and develop LPBs as vacci♦§∞₹nes in maximum three undisclosed§↕δ÷ indications. 4D has the rig♣ ht, subject to certain conditions, toγ™ purchase from MSD for $ 5 million ↔× common shares of 4D during the first 1₽≥ε2 months of the collaboration. In addi↓←≠δtion to an initial cash payment, for each indica↔φ✔tion, 4D will be eligible to re"★ceive up to $ 347.5 million $in exercise of options and regula₩tory and development milestone payments, as well ₽π€as royalties the annual net sales of any >&£licensed product resuσ↔∏ lting from the collaboration.≠★Duncan Peyton , CEO of 4D, ±™said, "This collaborative research agreeme÷©nt brings together 4D's×¥ innovations in the microbiome '♠←field and MSD's track record in the devπ✔©γelopment of advanced vaccines. MSD and 4D worked ÷≠↔©closely together combinε≈ing world-class scientific knowledge to d♥↔evelop a work plan to advance underst×♠★anding of this field, witα∑§÷h the goal of generating a new clasα∑s of vaccines in areas where unmet needs a₹&re important. "Daria Hazuda , Scientificπ↔ Director of MSD's Exploratory Science Center and&♣¥ Vice President of Research on MSD's ♠☆©Infectious Diseases aΩnd Vaccines Discovery, said, "A key element of oσ₩€ur goal at the Centeφ±r for Exploratory Science is the ass₩¥essment of emerging areas of≥ε emerging biology that are likely to have a ma≥★ jor beneficial impact on human healt↔ h. By applying MicroRx® technology o♦↔×f 4D, we hope to obtain useful i₽©nformation on the role of the host microbiome₩¥♣ in modulating the immuneπ≥≈ response and, ultimately, the protecπγtion conferred by vaccines€"α. "information sour™≠δφce:pharma focus AsiaThe original link:http→§s:https://www.pharmafocusasia.com/news/4d-pharma±↕-collaborates-with-msd-to-devel≤γop-live-biotherapeutic-products-for-vacc←¶→★ines2019 Asia-pacific pharma IP Leader₽ Summit: http://en.zenseegroup.com/p/5¥₩←α10934/will be held in Beijing ≠≤ on November 14-15,γ☆¥↓ and will attract more than 500 i>✘αndustry experts from domestic€< and foreign pharmaceutical compani∞≤∑es, biotechnology compan¥Ω&ies, governments, associatλφ♥ions, law firms, intellectual property a>δgents and other companies to att<↔π♣end.Official registration and con ≤sultation channels:Contact：AnnPhone:Ω< 021-65650305Email：Marketing@ze§™nseegroup.comhttp://en.zenseegroup.com/p/£γ×✔510934/ -
1009
Goldfinch Bio Announces Licensing Agreem" ₩ent with Takeda for CB1 Mono★™clonal Antibody for the Treatment δ∑§☆of Rare and Metabolic Kidney Di$β£∞seases
Goldfinch Bio, a U.S.-based, clinical stag∑←™₹e biotechnology company focused on disco§ε↔vering and developing precision medicines for ↔§€§the treatment of kid™ ∏ney diseases, today announce§ε×d it entered into a license ag∑ εreement with Takeda Pharmaceutical π Company Limited (“Takeda”) for worldwi§☆ ↔de rights to a preclinical, pe'↔ripherally-restricted cannabino ≈id receptor 1 (CB1) monoc𱕕lonal antibody. Goldfinch Bio will a×£ssume all development and commercialization resφ∏ponsibilities for the treatment of ra£≤✔★re and metabolic kidney diseases worldwiΩ↑✘de. However, the agreement grants Tak¶eda the option, prior to the init ™™iation of pivotal studies, to r♥©"equest Goldfinch Bio negotiate with Ta±€λkeda for sub-licensing of Japanese rights to Takeφε≥•da. Financial terms of the ag₹€πσreement were not disclosed. Goldfinch Bio pla∞→ns to file an investigational new drug (IND) app★♦♥lication for this CB1 inhibitor, re-named α GFB-024, in the second × half of 2020.“In recent year'↑s, our understanding of the role of CB1 signaling×→™§ in exacerbating progressive kidney λ€∑→diseases has grown substantially. In this co×↔ntext, a monoclonal antibody directπβed toward the CB1 recept± >or is potentially well-suited t'≥o elicit the beneficial pharmacology associ∞∑✘≈ated with the peripheral inhibition of the φ±☆₽CB1 receptor,” said Anthony Joh≈™βnson, M.D., Presiden♦γ↕t and Chief Executive Office∏✔r of Goldfinch Bio. “Goldf©§↔αinch Bio will deploy its biology platform aσ♥∞nd Kidney Genome AtlasTM δ≈₹to develop this therapeutic agδ♣ent in subsets of patients with kidney diseases€₩ most likely to preferentially respoλ®nd to CB1 inhibition. With GFB-887,$ our TRPC5 inhibitor for FSGS, in Phas★γe 1 clinical development, t∏φ↔✔his peripheral CB1 inhibitor will be the s₩≈♦econd clinic-ready progra<♣φ★m in Goldfinch Bio’s pipelinεγ®←e. We look forward t$'↓o collaborating with Takeda on this φδ'©program.”“Goldfinch Bio is ideally sui®ted to advance development ♣¶∏of this program,” said Dan Curran, M.D., SV→§£÷P and Head, Rare Diseases Therapeutic Are¶♥a Unit, Takeda. “The application of ©∑its precision medicine apλ© proach, from candidate target validation thro§±σugh to identification of potential treatment-rel↔π&evant subgroups, is unique in the λ♣development of chronδαic metabolic kidney disease treatments.”Precliniλφcal data support the inhibition of CBλ≤♣≤1 signaling as a novel treatment of D☆≠÷δiabetic Nephropathy (DN) and ↑≠π obesity-related glom★$↕εerulopathies (ORG), given the potential me'¥tabolic benefits and direct effeφπ₩cts on the kidney to÷↓ prevent fibrosis and preserφ"Ω©ve kidney function. DN develops in 30 to 40 perce<↑>∏nt of patients who have diaγ♦☆betes and is a leading cause&εε× of morbidity, mortality an↑↔d end-stage kidney disease in ♣¶the United States and worldwide. ORG is a rar •γe kidney disorder cha↕>racterized by significant proteinuria and<δ¶ progressive renal dysfunction. Although b≥₽oth DN and ORG are inc÷↑≤ reasing in prevalence in parall€σ£"el with the obesity epidemic, well-estab'₽±lished disease modifying therap© Ωies are lacking. Gold♥>finch Bio plans to initiate≠£≈ a phase 1 study for GFB-024 in 2H ♣ 2020.information sour ♥&λce:pharma focus AsiaThe original link:https://w₩€♥"ww.pharmafocusasia.com/ne€γ₹∏ws/goldfinch-bio-announces-licens ↕ing-agreement-with-taked≠♣♥a-for-cb1-monoclonal-antibody$σ♠β-for-the-treatment-of-rβ ₩≤are-and-metabolic-kidney-dise™↓ases2019 Asia-pacific pharma IP Leader Summit: ht♦>÷¶tp://en.zenseegroup.com/p/404716/ ♠↕will be held in Beijing on&≥≥≥≈nbsp;November 14-15, ←ε'≈and will attract more"'→ than 500 industry experts from dom'™Ω®estic and foreign ph↔≈armaceutical companies, biotechnology companies•$ , governments, associations, law firms, intell♠§ectual property agents and oth↕★er companies to attend.Official rβ¥∏egistration and consultation chann↓♦₹∞els:Contact：AnnPhone: 0✔∑21-65650305Email：Marketing@zenseegroup.comhttp:≈¥Ω&//en.zenseegroup.com/p/₽÷510934/ -
1008
Prometheus Biosciences, Inc., Eδ₽σ"nters Into Multi-Target Strategic Coll™δ×aboration with Takeda to Develop Targetedφ☆§↑ Therapies for Inflammato<↔ry Bowel Disease
Prometheus Biosciences, Incφσ✘€., a biopharmaceutical com✘↕pany committed to the discovery, development, " and commercialization of a broad portf$©olio of novel precision theπ™"↑rapeutics and companion § diagnostics for patients living with unmet✔← needs in gastroenterolo↔☆∑gy and autoimmune diseases, announced that it has₹ entered into a global, multi-target strategε✔∏∏ic collaboration with Takeda Pharmaceutical Co≈✔☆mpany Limited (Takeda) to discover, develo ™ε p, and commercialize novel therapies for™©≤→ inflammatory bowel disease (IBD). The colla&Ωboration combines the proprieta∞$☆♥ry bioinformatics discovery platform ε≥and companion diagnostic tools develo↑ped by Prometheus Biosciences wφ± ≥ith Takeda's expertise iקn gastroenterology and drug ♣development, in order to discover and β≠λadvance up to three targeted IBD therapeutics an&ε®d companion diagnostics.&n≠׶§bsp; Prometheus Biosciences will be res ✔ponsible for the identification ↔φ∑and validation of three u÷φnique drug targets for IBD, a♦€§♠long with the development and commercializatiΩ€φ☆on of companion diagn♥↔ostics to complement the targeted drugs§$€φ. Takeda will be respo' nsible for all drug ↑ discovery, clinical development, and comme≥♠πrcialization activities for the resu§ lting targeted therapeutics."We are impressed wi★₹♠th Takeda's commitment to deveα•loping a portfolio of therapies to address all ✔¶IBD patients, especially those with→♠ unmet needs," said Mark McKenna, chief executivπ ↑∑e officer, Prometheus Biosci™≥±ences. "We believe that a targeted, p←♠<recision medicine approach is n¶↔eeded to deliver new, efε¥÷fective therapeutic options in inf₹±€☆lammatory bowel disease. Through our partnership£≠ε, we are excited to combine the Prometheus bioinf'∞ ormatics platform and advanced machine le₩₽arning techniques with Takeda's expertis™™ ÷e in drug development to de'§liver a new generation of IBD the¥©←&rapies."Under the terms of the agreement≈σ, Prometheus Biosciences will receive ↔∞an undisclosed initial upfront paymentπ← from Takeda and is eligible to recei"""ve up to $420M in development, regulatory, andδ $' commercial milestone payments, inε™& total, across all t≠∞hree programs. In addition, Prometheε∑λus Biosciences is eligible to rec∏≤eive royalty payments on global commercial sales ↔≥×from each program.info↕×$rmation source:pharma focus AsiaThe orig£™<§inal link:https:https://www.pharmafocusasia.c≥≥∏↑om/news/prometheus-biosciences-inc-<®enters-into-multi-target-strategic-c≠©ollaboration-with-takeda-to-d↔π'evelop-targeted-therapies-for-inflammatory-b φowel-disease2019 Asia¥¶♣-pacific pharma IP Leader Summit: http¶₹δ±://en.zenseegroup.com/p/510934/ will be helβ>☆d in Beijing o∞≤n November 14-15, and wil® £l attract more than 500 industry experts from dom©∑>estic and foreign pharmace∏™utical companies, biotechnology co ÷∑≈mpanies, governments, asso¶≥>™ciations, law firms, intellectual property ag→✔β↕ents and other companies to attend≈≈≈§.Official registration and consultation chanα∏¥nels:Contact：AnnPhone: 021-65650305££Email：Marketing@zenseegrou↕✘p.comhttp://en.zenseegroup.com/p/510₩934/ -
0929
Catabasis Pharmaceuticals a∏≠nd the Jain Foundation Announce a Preclin≥↑ical Research Collaboration to Study Edasalon&±©exent in Dysferlinopathy
Catabasis Pharmaceuticals, Inc., a cl≤¥inical-stage biopharmaceutical company, and βδthe Jain Foundation, a non-profit ≈•σfoundation whose missio±©®n is to cure muscular dystrophies caused by dys∑φferlin protein deficiency, announced a p✘<reclinical research collaboration to study edasal≈γ ↕onexent (CAT-1004) in Dysferlinopathy♣σ. Dysferlinopathy (Limb-girdle muscular dys∞∞trophy type 2B / Miyoshi myopath↓>♦y) is a serious rare disease that c₽ ±auses progressive muscle weakness f≈©©δor which there are currently no appr÷πoved treatment optioγns. Edasalonexent is in Phase∏←•← 3 development for the treatment of Duc∞£henne muscular dystrophy (DMD) and ha•↑s the potential to benefit ≥∏≈patients with other di¥ seases, such as Dysferlinopathy.In Dysferlinopathy, muscles lack dysfδ≥₩erlin and as a result NF-kγ ♠✘B is chronically activatedδ≠€. Edasalonexent, an ora&∑★l small molecule desi×gned to inhibit NF-kB, has the pote≥♥ntial to slow disease progression in d÷♥ysferlin-deficient population÷λs. Under this collaboration, Catabasis and thΩe Jain Foundation are conducting a preclinical₽↑ study to evaluate the potenti$β&"al of edasalonexent →₹as a therapeutic intervention fo≈©✔r Dysferlinopathy by ε∏✔measuring disease progression in ∑dysferlin-deficient €§mice treated with edasalonexe&αnt. The study will utilize magnetic re→✔sonance imaging (MRI) and magnetic resonance≥'€¥ spectroscopy (MRS) to measure muscle volume, fa♦δ$t accumulation, and other changes in the dys™÷≥ ferlin-deficient mice.γβ÷ Initial results are expected in the first♥$£₽ half of 2020.“We look forward to working w♦ ¶∑ith Catabasis to advance research for Dysferπ©linopathy,” said Laura Rufibach, Ph.D., and Douπ&g Albrecht, Ph.D., Co-Pres&€±idents of the Jain Foundation. “Patients with ¶±&Dysferlinopathy (LGMD2B / Miyoshi myopathy) exper©≠ience a progressive and debilitating declin£>∏e in muscle function which sig×εnificantly impacts the$€±ir lives. As there are currently no treatm $ent options, we are excited to explore the pote ↔↓ntial of edasalonexent to benefit those living✔→± with this disease.”“The chronic activation of NF<≠-kB is a key driver in many n₩βeuromuscular disorders, including Duchenne mu÷λλλscular dystrophy. Evidence of NF-kB activation i®∞®n Dysferlinopathy suggests a simσ↔ilar disease mechanism and ∞γ opportunity for intervention. In the Mov®÷eDMD trial and open-label extension, tλπreatment with edasalonexent slowed dise<¶¥₹ase progression compared to t÷☆×he off-treatment control period. ♦ε☆εThrough this collaboratio§∏n, we look forward to learning more about th"αe potential of edasalonexent in Dysferlα→inopathy, where, similar to Duchenne, there is alε♦so a significant unmet n≥eed,” said Andrew Nichols, Ph.D., Chief Scientif♠≈ic Officer at Catabasi×λ™<s Pharmaceuticals.information source•α₽:pharma focus AsiaThe original link:https:https πβ://www.pharmafocusasia.com/news/catabasis-pharma↕£→ceuticals-and-the-jain-foundation-announce-a-preδ↕×clinical-research-collaboration-to-st÷₩σ™udy-edasalonexent-in-dys≈©↓ferlinopathy2019 Asia-pacifi↑$c pharma IP Leader Summit: http:/δ✔/en.zenseegroup.com/p/404716/& ∑∏≈nbsp;will be held in Beiji✔™ ng on November 14-15, and↔× will attract more than 500 industry experλ✘γts from domestic and foreign pharmaceutical compaβ'↕✔nies, biotechnology c$≤ompanies, governments, asπ®↔εsociations, law firms, intellectual property ag$γ∏λents and other companies to att♠¶★ end.Official registration and consu↓₽÷ltation channels:Contac•≠≈t：AnnPhone: 021-65650305Email：Marketing@zensee¥≠∞group.comhttp://en.zenseegroup.com/p/5β10934/ -
0927
NeuCyte Licenses Pro∑∞¶ mising Novel Compound for Trea§≤♣φtment of Refractory Epilepsy and RelaΩε≤↕ted Neurological Disorders
NeuCyte, Inc., an innovative biote₽☆ch company focused on developing novel t© δreatments for neurological disorders, todayΩ¥ announced that it has entered i₹↕φnto an exclusive license agreement with Trilliu¶σ→£m Therapeutics to advance an un≈★↑δdisclosed preclinical compou→σnd with potential utility in←>✘• treating refractory e←®★↔pilepsy in the form of Dravet syndrome"≥• and related disorders.The compound covered by tβ∏↓his agreement has demonstrated highly e∞♦ncouraging activity during studies conducted b←&y the National Institute of Neurol ≤ogical Disorders and Stλ↑♣γroke (NINDS) Epilepsy Therapy Screening Progra ≤m (ETSP). It demonstrates a super'©φ®ior safety and anti-seizure efficacy ∑★ profile over NINDS benchmark anti-epile∞≠ptic drugs (AEDs) in eleven animal models. It ✘£has also demonstrated broad efficacy ✔±©in NIH animal studies for phδ≥armaco-resistant epilepsy. As a result, thiφ₹±¶s novel agent has gained the prestigio☆λ¥≠us NINDS Red Book status and been÷€ selected as a promising leδ ¶ad drug candidate."Th&φ↑is compound is an exceedingly promising antise♦πizure drug which, although in preclin<£↕ical development, is q ✘♠↑uite efficacious in a wide variety of highly pred≥✔§ictive seizure models," said Roger®σπ J. Porter, MD, Adjunct Professor o₹☆×f Neurology at the University of Pennsylvaniλ<a, former Deputy Director of NINDS, f♦δ™₽ormer Chairman of the White House Committe₩Ωe on Brain and Behavioral Sc'☆÷iences, and former President of American Epileps₩¶¶y Society. "It may prove'φ↑× very effective for patient€±s with epilepsy." As a first-in-class >>≤εcompound with unique mechanism of action pγ↑φ±rofiles, this drug candidate is lik Ωφely to have activity across a variet∏✔y of indications. The favorable efficacy and sε♦↕afety profile has also been $≥<"validated by NeuCyte's proprietary in vitro h₹≠uman iPSC-derived mod↕ εels."Epilepsy is the fourth most common€β÷ neurological disease affecting λ←αmore than 65 million people of all ages worldw§δ>→ide. The complex and multif©÷♣actorial nature of the disordersσ£ makes treatment complicated and challenΩ₹πging. Up to 40% of newly₹≤ £ diagnosed epilepsy pat≤ ients are resistant to current therapiesβφ™€ which highlights the urgent need to deve€✔λlop first-in-class treatments," said Jacqueliγσ ne A. French, MD, Chief Medical ¥λ&and Innovation Officer of the Epilepsy Fouπ∞ ndation and epileptologist in ≥↔≤New York City. "It is veryΩε encouraging to see new developments and therape↕>♣utic candidates in this disease area."Under the ≈<terms of the agreementα♥♣, Trillium has granted NeuCyte exclusiβ ♠∏ve, worldwide rights to develop and commerciali☆♣ze the compound. ↔£∑Ω"NeuCyte is committed to bringing breakthrΩ≥§πough therapies to epilepsy pa" ★λtients and believe that our β★advantageous translational technology★≈← platform and CNS expertise enable us to optiλ♦εmally advance such the<Ω™×rapeutic candidates," said Tao H↔Ωuang, PhD, JD, President and Chieλ₩✘ f Executive Officer of NeuCyte. "This lic™&ε ensing agreement allows us♠÷' to expand our pipeline and advance o™≠ur goal of meeting unmet clinical needs an> d truly improving patient care and quality of lif£εe."information source:phaπ>>™rma focus AsiaThe original link:https:https:htt©₹ps://www.pharmafocusasia.com/new↕↓s/neucyte-licenses-promising-novel-compound-for-tφ↓↓☆reatment-of-refractory-epilepsy-and-rela✔ ≥ted-neurological-disorders2019 ↔γ•☆Asia-pacific pharma IP L★λ•eader Summit:http://en.zenseegroup.com/p/510934/w¶ ill be held in ♥•βBeijing o©•"₹n November 14-15, and wi±®♥ll attract more than 500 industry experts from do≤↔×mestic and foreign pharmace★÷utical companies, biotechnology companies,Ωπ<↑ governments, associations, law fi★€₩rms, intellectual property agents and ot≤∏∏her companies to attend.Official rπ→ε☆egistration and consultation channels:Conta ¥↕≠ct：AnnPhone: 021-65650305Email：Marketing@ze♥"β÷nseegroup.comhttp://en.zens £>γeegroup.com/p/510934/
Contact Us
Zensee_Daystar online
© 2011-2016